等待开盘 12-22 09:30:00 美东时间
-0.180
-0.95%
Avalo Therapeutics appoints Rita Jain, M.D., to its Board of Directors, enhancing its leadership in advancing AVTX-009, a Phase 2 anti-IL-1β antibody for hidradenitis suppurativa and other inflammatory diseases.
06-18 11:00
<p>Study highlights that AVITA Medical's RECELL technology reduces hospital stays and costs for burn patients, offering a more efficient and less painful alternative to traditional skin grafts.</p>
06-09 13:00
Avalo Therapeutics announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4 and the Oppenheimer Innovators in I&I Summit on June 25. The company focuses on treating immune dysregulation, with its lead asset being AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases.
05-27 14:05
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM). Nikola shares dipped 10.4% to $7.28 on Monday. Here are some other stocks moving in tod...
2024-09-04 01:41
Avalo Therapeutics 13G Filing Shows BVF Partners L.P. Reported a 9.99% Stake In The Co As Of August 13, 2024
2024-08-24 04:39